Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Imaging And Path LabBOM:544482 -2.22%21 EBIT per Share is ₹16.22 as of Mar. 2026. GuruFocus rates BOM:544482 with a GF Score™ of 21/100. Among 163 Medical Diagnostics & Research companies, Star Imaging And Path Lab ranks better than 99.39% on this metric.
Star Imaging And Path Lab's EBIT per Share for the
six
months ended in Mar. 2026 was ₹7.71.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹16.22.
During the past 12 months, the average EBIT per Share Growth Rate of Star Imaging And Path Lab was 23.40% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 138.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Star Imaging And Path Lab's EBIT per Share or its related term are showing as below:
BOM:544482'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 28.5 Med: 83.6 Max: 138.7
Current: 138.7
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Star Imaging And Path Lab was 138.70% per year. The lowest was 28.50% per year. And the median was 83.60% per year.
BOM:544482's 3-Year EBIT Growth Rate is ranked better than 99.39% of 163
companies
in the Medical Diagnostics & Research industry
Industry Median: 13
vs BOM:544482: 138.70
Star Imaging And Path Lab (BOM:544482) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Star Imaging And Path Lab EBIT per Share Related Terms
Star Imaging And Path Lab EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹16.22
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Imaging And Path Lab (BOM:544482) has a EBIT per Share of ₹16.22 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Star Imaging And Path Lab and its competitors. According to the industry distribution chart, Star Imaging And Path Lab ranks #1 out of 163 companies in the Medical Diagnostics & Research industry, placing it in the top 0.59999999999999%.
Is Star Imaging And Path Lab's EBIT per Share too high?
Star Imaging And Path Lab's current EBIT per Share is ₹16.22. Based on the distribution chart, Star Imaging And Path Lab ranks #1 out of 163 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Star Imaging And Path Lab has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Star Imaging And Path Lab's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Star Imaging And Path Lab ranks #1 out of 163 companies for EBIT per Share. This places Star Imaging And Path Lab in the top 1% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 13.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.00, based on 163 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Star Imaging And Path Lab and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Imaging And Path Lab's current EBIT per Share is ₹16.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Imaging And Path Lab stock overvalued right now?
Star Imaging And Path Lab (BOM:544482) has a current EBIT per Share of ₹16.22. The current EBIT per Share is ₹16.22. Star Imaging And Path Lab's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Star Imaging And Path Lab (BOM:544482), the current EBIT per Share is ₹16.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Star Imaging And Path Lab Ltd operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi and Uttar Pradesh. It offers a comprehensive range of diagnostic imaging services and clinical laboratory tests, including both routine and specialized studies and profiles. These services are essential for the prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. The company's diagnostic imaging and radiology services encompass X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, ultrasounds, bone mineral densitometry, and mammography.
21GF Score
Get the complete analysis for BOM:544482
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544482 has been successfully added to your 
